RESUMEN
Prorenin is viewed as an ideal target molecule in the prevention of diabetic retinopathy. However, no drugs are available for inhibiting activation of prorenin. Here, we tested the effect of a prorenin peptide vaccine (VP) in the retina of a murine model of type 2 diabetes (T2D). To choose the optimal vaccine, we selected three different epitopes of the prorenin prosegment (E1, E2, and E3) and conjugated them to keyhole limpet hemocyanin (KLH). We injected C57BL/6J mice twice with KLH only (as a control vaccine), E1 conjugated with KLH (E1-KLH), E2-KLH, or E3-KLH and compared antibody titers. E2-KLH showed the highest antibody titer and specific immunoreactivity of anti-sera against prorenin, so we used E2-KLH as VP. Then, we administered injections to the non-diabetic db/m and diabetic db/db mice, as follows: db/m + KLH, db/db + KLH, and db/db + VP. Retinal blood flow measurement with laser speckle flowgraphy showed that the impaired retinal circulation response to both flicker light and systemic hyperoxia in db/db mice improved with VP. Furthermore, the prolonged implicit time of b-wave and oscillatory potentials in electroretinography was prevented, and immunohistochemical analysis showed reduced microglial activation, gliosis, and vascular leakage. The enzyme-linked immunosorbent spot assay confirmed vaccinated mice had no auto-immune response against prorenin itself. The present data suggest that vaccination against prorenin is an effective and safe measure against the early pathological changes of diabetic retinopathy in T2D.
Asunto(s)
Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Retinopatía Diabética/prevención & control , Inmunoterapia/métodos , Receptores de Leptina/fisiología , Renina/inmunología , Vacunas de Subunidad/administración & dosificación , Animales , Retinopatía Diabética/etiología , Retinopatía Diabética/metabolismo , Modelos Animales de Enfermedad , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Precursores de Proteínas/inmunología , VacunaciónRESUMEN
The hormone renin plays a crucial role in the regulation of blood pressure and fluid-electrolyte homeostasis. Normally, renin is synthesized by juxtaglomerular (JG) cells, a specialized group of myoepithelial cells located near the entrance to the kidney glomeruli. In response to low blood pressure and/or a decrease in extracellular fluid volume (as it occurs during dehydration, hypotension, or septic shock) JG cells respond by releasing renin to the circulation to reestablish homeostasis. Interestingly, renin-expressing cells also exist outside of the kidney, where their function has remained a mystery. We discovered a unique type of renin-expressing B-1 lymphocyte that may have unrecognized roles in defending the organism against infections. These cells synthesize renin, entrap and phagocyte bacteria and control bacterial growth. The ability of renin-bearing lymphocytes to control infections-which is enhanced by the presence of renin-adds a novel, previously unsuspected dimension to the defense role of renin-expressing cells, linking the endocrine control of circulatory homeostasis with the immune control of infections to ensure survival.
Asunto(s)
Bacterias/inmunología , Infecciones Bacterianas/inmunología , Diferenciación Celular/inmunología , Regulación Enzimológica de la Expresión Génica/inmunología , Linfocitos/inmunología , Renina/inmunología , Animales , Ratones , Ratones Transgénicos , Renina/genéticaRESUMEN
CONTEXT: Not all obese individuals develop cardiovascular disease (CVD). Hyperaldosteronism is suggested to cause inflammation and metabolic dysregulation, and might contribute to CVD development in obese individuals. OBJECTIVE: We aimed to investigate the association of aldosterone concentrations with inflammation, metabolic disturbances, and atherosclerosis in overweight and obese individuals. Additionally, we measured renin concentrations to investigate whether the observed effects reflected general activation of the renin-angiotensin-aldosterone system (RAAS). DESIGN: A cross-sectional cohort study (300-OB study) was conducted. Various inflammatory parameters, traits of the metabolic syndrome, lipidome and metabolome parameters, fat distribution, and carotid atherosclerosis were associated with plasma aldosterone and renin levels. SETTING: The setting of this study was the Radboudumc (i.o. Radboudumc), the Netherlands. PATIENTS: A total of 302 individuals with a body mass index greater than or equal to 27 kg/m2 participated. MAIN OUTCOME MEASURES AND RESULTS: Aldosterone was associated with various markers of inflammation and metabolic dysregulation, which partly differed from the associations observed for renin. Although both were associated with inflammatory cell numbers, only renin was associated with classical markers of systemic inflammation. Both were associated with the metabolic syndrome and hepatic steatosis. Of the traits that constitute metabolic syndrome, aldosterone, but not renin, was associated with triglyceride concentrations. Accordingly, aldosterone was associated with large very low-density lipoprotein particles; metabolomics studies further associated aldosterone with urate concentrations and derivatives of the linoleic acid metabolism pathway. Neither aldosterone nor renin was associated with atherosclerotic plaque thickness. CONCLUSIONS: Aldosterone is not an important driver of systemic inflammation in the obese, whereas aldosterone concentrations and metabolic dysregulation are strongly intertwined in these individuals. Although prospective studies are necessary to validate these results, the independent effects of aldosterone on carotid atherosclerosis appear modest.
Asunto(s)
Aldosterona/sangre , Aterosclerosis/diagnóstico , Hiperaldosteronismo/diagnóstico , Inflamación/diagnóstico , Síndrome Metabólico/diagnóstico , Obesidad/complicaciones , Anciano , Anciano de 80 o más Años , Aldosterona/inmunología , Aterosclerosis/sangre , Aterosclerosis/etiología , Biomarcadores/sangre , Arterias Carótidas/diagnóstico por imagen , Estudios Transversales , Ayuno/sangre , Femenino , Humanos , Hiperaldosteronismo/complicaciones , Hiperaldosteronismo/inmunología , Hiperaldosteronismo/metabolismo , Inflamación/sangre , Inflamación/inmunología , Inflamación/metabolismo , Ácido Linoleico/sangre , Ácido Linoleico/metabolismo , Lipoproteínas VLDL/sangre , Lipoproteínas VLDL/metabolismo , Imagen por Resonancia Magnética , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/inmunología , Síndrome Metabólico/metabolismo , Metabolómica , Persona de Mediana Edad , Países Bajos , Obesidad/sangre , Obesidad/inmunología , Obesidad/metabolismo , Renina/sangre , Renina/inmunología , Triglicéridos/sangre , Triglicéridos/metabolismoRESUMEN
Cardiovascular disease and infections are directly or indirectly associated with an altered immune response, which leads to a high incidence of morbidity and mortality, and together, they account for up to 70% of all deaths among patients with chronic kidney dysfunction. Impairment of the normal reaction of the innate and adaptive immune systems in chronic kidney disease predisposes patients to an increased risk of infections, virus-associated cancers, and a diminished vaccine response. On the other hand, an abnormal, exaggerated reaction of the immune systems can also occur in this group of patients, resulting in increased production and decreased clearance of proinflammatory cytokines, which can lead to inflammation and its sequelae (eg, atherosclerotic cardiovascular disease). Epigenetically, modifications in hematopoietic stem cells involving a shift from lymphoid to myeloid cell lineage may underlie uremia-associated immunological senescence, which is not reversed by renal replacement therapy, including kidney transplantation. Measures aimed at attenuating the immune abnormalities in chronic kidney disease/end-stage renal disease should be an area of focused research as this could potentially lead to a better understanding and, thus, development of therapies that could reduce the disastrously high death rate in this patient population. The aim of the present article is to review the characteristics, causes, and mechanisms of the immune dysfunction related to chronic kidney disease.
Asunto(s)
Huésped Inmunocomprometido/inmunología , Infecciones/inmunología , Inflamación/inmunología , Insuficiencia Renal Crónica/inmunología , Inmunidad Adaptativa/inmunología , Calcitriol/inmunología , Calcio/metabolismo , Epigénesis Genética , Eritropoyetina/inmunología , Factor-23 de Crecimiento de Fibroblastos , Factores de Crecimiento de Fibroblastos/metabolismo , Microbioma Gastrointestinal/inmunología , Células Madre Hematopoyéticas/metabolismo , Humanos , Inmunidad Innata/inmunología , Huésped Inmunocomprometido/genética , Inmunosenescencia , Infecciones/epidemiología , Hierro/inmunología , Estrés Oxidativo/inmunología , Hormona Paratiroidea/metabolismo , Insuficiencia Renal Crónica/epidemiología , Insuficiencia Renal Crónica/genética , Insuficiencia Renal Crónica/terapia , Terapia de Reemplazo Renal , Renina/inmunología , Sistema Renina-Angiotensina/inmunología , Vitamina D/metabolismoRESUMEN
Human cytomegalovirus (HCMV) infection, chronic inflammation and oxidative stress, the renin-angiotensin system (RAS), endothelial function, and DNA methylation play roles in the pathogenesis of essential hypertension (EH); however, the mechanism by which HCMV predisposes patients to hypertension remain unclear. Our group previously demonstrated an association between EH and HCMV infection in Kazakh Chinese. Here, we investigated the relationship between HCMV infection and other clinicopathological features in 720 Kazakh individuals with or without hypertension (n=360 each; age: 18-80). Multiple linear and logistic regression analyses were used to determine the associations between HCMV infection, clinical characteristics, and EH. Notably, patients with EH, particularly those with HCMV infection, exhibited a marked increase in tumor necrosis factor-α (TNF-α) and 8-hydroxy-2-deoxyguanosine (8-OHDG) levels, but a decrease in endothelial nitric oxide synthase (eNOS) and renin levels. Similarly, elevated TNF-α and 8-OHDG levels were independent predictors of increased HCMV antibody titers, whereas eNOS and renin were negatively correlated with the latter. Moreover, serum angiotensin-converting enzyme (sACE, ACE) methylation was increased, whereas 11-ß hydroxysteroid dehydrogenase 2 (HSD11ß2; HSD3B2) methylation was decreased in patients with EH who were also infected with HCMV. A positive correlation between HSD3B2 methylation and HCMV IgG titer and blood pressure was additionally observed, whereas angiotensin-converting enzyme (ACE) methylation was inversely correlated with blood pressure. Collectively, these data indicate that HCMV may contribute to EH development in the Kazakh Chinese by increasing TNF-α and 8-OHDG levels, suppressing eNOS and renin, and manipulating HSD3B2 and ACE methylation.
Asunto(s)
Infecciones por Citomegalovirus/virología , Desoxiguanosina/análogos & derivados , Hipertensión Esencial/virología , Óxido Nítrico Sintasa de Tipo III/inmunología , Renina/inmunología , Factor de Necrosis Tumoral alfa/inmunología , 8-Hidroxi-2'-Desoxicoguanosina , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antivirales/sangre , Presión Sanguínea , Estudios de Casos y Controles , China , Citomegalovirus/genética , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/complicaciones , Infecciones por Citomegalovirus/etnología , Infecciones por Citomegalovirus/inmunología , Desoxiguanosina/sangre , Desoxiguanosina/inmunología , Hipertensión Esencial/complicaciones , Hipertensión Esencial/etnología , Hipertensión Esencial/inmunología , Etnicidad , Femenino , Humanos , Masculino , Metilación , Persona de Mediana Edad , Óxido Nítrico Sintasa de Tipo III/sangre , Peptidil-Dipeptidasa A/sangre , Peptidil-Dipeptidasa A/inmunología , Progesterona Reductasa/sangre , Progesterona Reductasa/inmunología , Renina/sangre , Factor de Necrosis Tumoral alfa/sangreRESUMEN
The initiation or progression of periodontitis might involve a local renin-angiotensin system (RAS) in periodontal tissue. The aim of this study was to further characterize the local RAS in human and rat periodontal tissues between healthy and periodontally-affected tissue. Components of the RAS were investigated using in vitro, ex vivo and in vivo experiments involving both human and Wistar rat periodontium. Although not upregulated when challenged with P. gingivalis-lipopolysaccharide, human gingival and periodontal ligament fibroblasts expressed RAS components. Likewise, healthy and inflamed human gingiva expressed RAS components, some of which were shown to be functional, yet no differences in expression were found between healthy and diseased gingiva. However, in inflamed tissue the immunoreactivity was greater for the AT1R compared to AT2R in fibroblasts. When compared to healthy tissue, ACE activity was increased in human gingiva from volunteers with gingivitis. Human-gingiva homogenates generated Ang II, Ang 1-9 and Ang 1-7 when incubated with precursors. In gingiva homogenates, Ang II formation from Ang I was nearly abolished only when captopril and chymostatin were combined. Ang 1-7 formation was significantly greater when human gingiva homogenates were incubated with chymostatin alone compared to incubation without any inhibitor, only captopril, or captopril and chymostatin. In rat gingiva, RAS components were also found; their expression was not different between healthy and experimentally induced periodontitis (EP) groups. However, renin inhibition (aliskiren) and an AT1R antagonist (losartan) significantly blocked EP-alveolar-bone loss in rats. Collectively, these data are consistent with the hypothesis that a local RAS system is not only present but is also functional in both human and rat periodontal tissue. Furthermore, blocking AT1R and renin can significantly prevent periodontal bone loss induced by EP in rats.
Asunto(s)
Periodontitis/inmunología , Periodontitis/patología , Periodoncio/inmunología , Periodoncio/patología , Sistema Renina-Angiotensina , Adulto , Secuencia de Aminoácidos , Angiotensina I/análisis , Angiotensina I/inmunología , Angiotensina II/análisis , Angiotensina II/inmunología , Animales , Células Cultivadas , Femenino , Encía/citología , Encía/inmunología , Encía/patología , Humanos , Inflamación/inmunología , Inflamación/patología , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/análisis , Fragmentos de Péptidos/inmunología , Ratas Wistar , Receptores de Angiotensina/análisis , Receptores de Angiotensina/inmunología , Renina/inmunología , Adulto JovenRESUMEN
Vaccination provides a promising approach for treatment of hypertension and improvement in compliance. As the initiation factor of renin-angiotensin system, renin plays a critical role in hypertension. In this study, we selected six peptides (rR32, rR72, rR215, hR32, hR72, and hR215) belonging to potential epitopes of rat and human renin. The main criteria were as follows: (1) include one of renin catalytic sites or the flap sequence; (2) low/no-similarity when matched with the host proteome; (3) ideal antigenicity and hydrophilicity. The peptides were coupled to keyhole limpet hemocyanin and injected into SpragueDawley (SD) rats, spontaneously hypertensive rats (SHRs) and Wistar-Kyoto rats. The antisera titers and the binding capacity with renin were detected. The effects of the anti-peptides antibodies on plasma renin activity (PRA) and blood pressure were also determined. All peptides elicited strong antibody responses. The antisera titers ranged from 1:32,000 to 1:80,000 in SD rats on day 63. All antisera could bind to renin in vitro. Compared with the control antibody, the antibodies against the rR32, hR32, rR72 and hR72 peptides inhibited PRA level by up to about 50%. Complete cross-reactivity of the anti-rR32 antibody and the anti-hR32 antibody was confirmed. The epitopes rR32 and hR32 vaccines significantly decreased systolic blood pressure (SBP) of SHRs up to 15mmHg (175±2 vesus 190±3 mmHg, Pâ=â0.035; 180±2 vesus 195±3 mmHg, Pâ=â0.039), while no obvious effect on SD rats. Additionally, no significant immune-mediated damage was detected in the vaccinated animals. In conclusion, the antigenic peptide hR32 vaccine mimicking the (32)Asp catalytic site of human renin may constitute a novel tool for the development of a renin vaccine.
Asunto(s)
Antihipertensivos/inmunología , Renina/inmunología , Vacunas de Subunidad/inmunología , Secuencia de Aminoácidos , Angiotensina II/metabolismo , Animales , Especificidad de Anticuerpos , Antihipertensivos/química , Presión Sanguínea/inmunología , Dominio Catalítico , Reacciones Cruzadas , Humanos , Inmunoglobulina G/inmunología , Ratas , Ratas Endogámicas SHR , Renina/sangre , Renina/química , Vacunación , Vacunas de Subunidad/químicaAsunto(s)
Síndrome de Secreción Inadecuada de ADH/diagnóstico , Aparato Yuxtaglomerular/patología , Neoplasias Renales/diagnóstico , Neoplasias Primarias Múltiples/diagnóstico , Síndromes Paraneoplásicos/patología , Renina/aislamiento & purificación , Antagonistas de los Receptores de Hormonas Antidiuréticas , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Benzazepinas/uso terapéutico , Dacarbazina/administración & dosificación , Desoxicitidina/administración & dosificación , Desoxicitidina/análogos & derivados , Diagnóstico Diferencial , Progresión de la Enfermedad , Doxorrubicina/administración & dosificación , Humanos , Hiponatremia/tratamiento farmacológico , Hiponatremia/etiología , Ifosfamida/administración & dosificación , Inmunohistoquímica , Inmunofenotipificación , Síndrome de Secreción Inadecuada de ADH/patología , Neoplasias Renales/química , Neoplasias Renales/complicaciones , Neoplasias Renales/tratamiento farmacológico , Neoplasias Renales/patología , Mediciones Luminiscentes , Masculino , Persona de Mediana Edad , Neoplasias Primarias Múltiples/química , Neoplasias Primarias Múltiples/complicaciones , Neoplasias Primarias Múltiples/tratamiento farmacológico , Neoplasias Primarias Múltiples/patología , Paclitaxel/administración & dosificación , Renina/inmunología , Tolvaptán , Vinblastina/administración & dosificación , Vinblastina/análogos & derivados , Vinorelbina , GemcitabinaRESUMEN
Renin inhibitors like aliskiren not only block renin but also bind prorenin, thereby inducing a conformational change (like the change induced by acid) allowing its recognition in a renin-specific assay. Consequently, aliskiren can be used to measure prorenin. VTP-27999 is a new renin inhibitor with an aliskiren-like IC50 and t1/2, and a much higher bioavailability. This study addressed (pro)renin changes during treatment of volunteers with VTP-27999 or aliskiren. Both drugs increased renin immunoreactivity. Treatment of plasma samples from aliskiren-treated subjects with excess aliskiren yielded higher renin immunoreactivity levels, confirming the presence of prorenin. Unexpectedly, this approach did not work in VTP-27999-treated subjects, although an assay detecting the prosegment revealed that their blood still contained prorenin. Subsequent in vitro analysis showed that VTP-27999 increased renin immunoreactivity for a given amount of renin by ≥ 30% but did not unfold prorenin. Yet, it did bind to acid-activated, intact prorenin and then again increased immunoreactivity in a renin assay. However, no such increase in immunoreactivity was seen when measuring acid-activated prorenin bound to VTP-27999 with a prosegment-directed assay. The VTP-27999-induced rises in renin immunoreactivity could be competitively prevented by aliskiren, and antibody displacement studies revealed a higher affinity of the active site-directed antibodies in the presence of VTP-27999. In conclusion, VTP-27999 increases renin immunoreactivity in renin immunoassays because it affects the affinity of the active site-directed antibody. Combined with its lack of effect on prorenin, these data show that VTP-27999 differs from aliskiren. The clinical relevance of these results needs to be established.
Asunto(s)
Amidas/farmacología , Fumaratos/farmacología , Desplegamiento Proteico/efectos de los fármacos , Renina/antagonistas & inhibidores , Renina/química , Renina/inmunología , Adulto , Carbamatos/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Semivida , Humanos , Inmunoensayo , Masculino , Piperidinas/farmacología , Unión Proteica/efectos de los fármacos , Renina/sangre , Renina/efectos de los fármacosRESUMEN
Inflammation and activation of immunity are central features in the pathogenesis of atherosclerosis, ischemic myocardial injury, and hypertension-induced target-organ damage. The renin-angiotensin-aldosterone system can initiate not only innate but also acquired immunity. The latter process includes formation of activating antibodies directed at the angiotensin (Ang) II receptor. Ang II not only regulates vascular tone and sodium balance, but also activates immune cells and promotes cell infiltration into target organs. Studies showed that macrophages and various T cell subtypes play a pivotal role in target-organ damage and even in the regulation of blood pressure and responses to Ang II. Experimental and clinical evidence shows that adaptive transfer of immune cells, rendering mice deficient for a certain subset of immune cells, or immunosuppressive treatment affects blood pressure and ameliorates target-organ damage. Neural mechanisms interact with and regulate these processes. Understanding the mechanisms could direct us to novel therapies.
Asunto(s)
Angiotensina II/inmunología , Enfermedades Cardiovasculares/inmunología , Sistema Renina-Angiotensina/inmunología , Inmunidad Adaptativa , Animales , Autoinmunidad , Vasos Sanguíneos/inmunología , Encéfalo/inmunología , Proteínas del Sistema Complemento , Humanos , Inmunidad Innata , Inflamación/complicaciones , Riñón/inmunología , Linfocitos , Miocardio/inmunología , FN-kappa B/inmunología , Renina/inmunología , Renina/metabolismoRESUMEN
Measurement of renin is important for the clinical assessment of hypertensive patients and for the screening for primary aldosteronism. The aim of this study was to evaluate the performances of an automated immunoassay for measurement of immunoreactive renin. Functional sensitivity, in vitro stability, and reference values were determined. Method comparison with the plasma renin activity assay was also performed. Our results demonstrate that the Liaison(®) direct renin assay may assist the clinician in the assessment of hypertensive patients and in the screening for primary aldosteronism.
Asunto(s)
Inmunoensayo/métodos , Mediciones Luminiscentes/métodos , Renina/sangre , Biomarcadores/sangre , Diagnóstico Diferencial , Humanos , Hiperaldosteronismo/sangre , Hiperaldosteronismo/diagnóstico , Hipertensión/sangre , Hipertensión/diagnóstico , Tamizaje Masivo , Valores de Referencia , Renina/inmunología , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: Primary hyperaldosteronism (PHA) is characterized by a raised plasma aldosterone concentration (PAC) with suppressed plasma renin activity (PRA). We evaluated two renin mass methods for PHA detection compared with the PAC:PRA ratio. METHODS: Samples from patients attending a specialist hypertensive clinic were analysed by Liaison automated chemiluminescent immunoassay and Diagnostic Systems Laboratories (DSL) immunoradiometric assay (IRMA) for renin mass; I(-125) radioimmunoassay of angiotensin I generated from endogenous angiotensinogen for PRA; Siemens Coat-a-count radioimmunoassay for PAC. Subjects included those on ß-blockers which suppress renin, causing an equivalent biochemical picture to PHA. Aldosterone/renin ratios (ARR) were calculated for PRA, DSL and Liaison methods. The first 100 subjects were used to identify cut-off ratios ensuring maximum specificity at 100% sensitivity for PHA detection. This cut-off was retested in a subsequent population (n = 43). RESULTS: A Liaison renin of 5 ng/L separated PRAs of ≤0.5 from ≥0.6 pmol/mL/h. The DSL method had greater scatter. In population 1 (18 PHA), cut-off ratios of >118 pmol/ng (Liaison) and >60 pmol/ng (DSL) gave specificities of 58.5% and 61%, respectively, with 100% sensitivity. If criteria for PHA included PAC ≥350 pmol/L and excluded ß-blocked subjects, specificity increased to 95.1% and 90% for Liaison and DSL, respectively. In population 2 (6 PHA), specificities for Liaison and DSL ARRs were 86.4% and 78.3%. Using the ratio with PAC and ß-blocker criteria, specificities for Liaison and DSL were 97.3% and 86.5%, respectively. CONCLUSIONS: The Liaison ARR used with PAC and ß-blocker criteria provided an automatable alternative to identify the same patients as the PAC:PRA ratio.
Asunto(s)
Análisis Químico de la Sangre/métodos , Hiperaldosteronismo/sangre , Hiperaldosteronismo/metabolismo , Ensayo Inmunorradiométrico/métodos , Renina/sangre , Renina/metabolismo , Adulto , Anciano , Aldosterona/sangre , Aldosterona/inmunología , Criopreservación , Femenino , Humanos , Hiperaldosteronismo/diagnóstico , Masculino , Persona de Mediana Edad , Curva ROC , Renina/inmunologíaRESUMEN
IMPORTANCE OF THE FIELD: In the USA only 35% of patients with hypertension achieve adequate blood pressure control. Non-compliance is one of the main barriers to treatment. Vaccine against hypertension is an innovative treatment, injected every 4 - 6 months, to combat non-compliance. AREAS COVERED IN THIS REVIEW: Pathogenesis of hypertension and progress towards developing a hypertension vaccine, including the virus-like-particle-based approach, new adjuvant molecules and the potential toxicity of hypertension vaccine. WHAT THE READER WILL GAIN: The pathogenesis of hypertension is multifactorial. The most common cause is disruption of the Renin-angiotensin-aldosterone system (RAAS), and the first vaccine study was carried out against renin. While the vaccine reduced blood pressure in animal models, it also caused autoimmune disease. In the last decade, vaccines against angiotensin I, angiotensin II, and angiotensin II-type 1 receptors have demonstrated acceptable safety profiles in animal and human studies. TAKE HOME MESSAGE: Reduction in blood pressure can be achieved by inducing immunity against targets in the RAAS. The target antigen and selection of adjuvant are crucial factors determining effectiveness and safety of the vaccine. CYT006-AngQb (angiotensin II vaccine) reduced blood pressure in humans but the results were not reproducible with more frequent dosing. Vaccines for hypertension are still in the early phase. We hope for an effective vaccine for hypertension in the years to come.
Asunto(s)
Hipertensión/terapia , Sistema Renina-Angiotensina/inmunología , Vacunas/uso terapéutico , Angiotensina I/inmunología , Angiotensina II/inmunología , Animales , Presión Sanguínea , Humanos , Hipertensión/inmunología , Hipertensión/fisiopatología , Oligopéptidos/inmunología , Oligopéptidos/uso terapéutico , Receptor de Angiotensina Tipo 1/inmunología , Renina/inmunología , Resultado del Tratamiento , Vacunas/efectos adversos , Vacunas/inmunologíaRESUMEN
Immunologic approaches to renin-angiotensin-aldosterone system (RAAS) inhibition have been studied for more than 50 years. In animal models, vaccination against renin was effective but resulted in fatal autoimmune renal disease; vaccines directed at small peptides including angiotensin I and II and a segment of the AT(1) receptor reduced blood pressure (BP) without causing autoimmune disease. In humans, angiotensin I vaccination did not reduce BP. More promising is the AngQb vaccine, which uses an immunization technology involving conjugation of angiotensin II to virus-like particles. In a phase 2 trial, hypertensive patients vaccinated with 300 microg showed a difference of 9.0/4.0 mm Hg from baseline in mean daytime ambulatory BP after 14 weeks (P = 0.015 for systolic BP, P = 0.064 for diastolic BP), and a marked reduction in early morning BP. No serious adverse events were attributed to vaccine administration. Although questions remain regarding efficacy and safety, RAAS immunization represents an innovative and promising approach to hypertension treatment.
Asunto(s)
Hipertensión/prevención & control , Sistema Renina-Angiotensina/inmunología , Vacunación/métodos , Vacunas/inmunología , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Angiotensinas/inmunología , Angiotensinas/farmacología , Animales , Estudios de Cohortes , Modelos Animales de Enfermedad , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Hipertensión/inmunología , Renina/inmunología , Renina/farmacología , Sistema Renina-Angiotensina/efectos de los fármacos , Medición de Riesgo , Sensibilidad y Especificidad , Vacunas/farmacologíaRESUMEN
Binding of a panel of eight monoclonal antibodies (mAbs) with the C domain of angiotensin converting enzyme (ACE) to human testicular ACE (tACE) (corresponding to the C domain of the somatic enzyme) was studied and the inhibition of the enzyme by the mAb 4E3 was found. The dissociation constants of complexes of two mAbs, IB8 and 2H9, with tACE were 2.3 +/- 0.4 and 2.5 +/- 0.4 nM, respectively, for recombinant tACE and 1.6 +/- 0.3 nM for spermatozoid tACE. Competition parameters of mAb binding with tACE were obtained and analyzed. As a result, the eight mAbs were divided into three groups, whose binding epitopes did not overlap: (1) 1E10, 2B11, 2H9, 3F11, and 4E3; (2) 1B8 and 3F10; and (3) IB3. A diagram demonstrating mAb competitive binding with tACE was proposed. Comparative analysis of mAb binding to human and chimpanzee ACE was carried out, which resulted in revealing of two amino acid residues, Lys677 and Pro730, responsible for binding of three antibodies, 1E10, 1B8, and 3F10. It was found by mutation of Asp616 located close to Lys677 that the mAb binding epitope 1E10 contains Asp616 and Lys677, whereas mAbs 1B8 and 3F10 contain Pro730.
Asunto(s)
Anticuerpos Monoclonales/química , Renina/química , Secuencia de Aminoácidos , Inhibidores de la Enzima Convertidora de Angiotensina/química , Inhibidores de la Enzima Convertidora de Angiotensina/inmunología , Animales , Anticuerpos Monoclonales/inmunología , Unión Competitiva , Epítopos , Humanos , Masculino , Datos de Secuencia Molecular , Pan troglodytes , Unión Proteica , Estructura Terciaria de Proteína , Renina/sangre , Renina/inmunología , Espermatozoides/enzimologíaRESUMEN
With increased understanding of the pharmacology of the renin-angiotensin system (RAS), many researchers have explored immunological approaches to inhibit components of the RAS for the treatment of hypertension. Active and passive immunizations of the various components of the RAS have been performed, utilizing renin, angiotensin I, angiotensin II and angiotensin II receptor type 1 vaccines. This review discusses the RAS as a target for the development of a hypertension vaccine, and evaluates the safety and efficacy of these vaccines.
Asunto(s)
Hipertensión/terapia , Sistema Renina-Angiotensina/fisiología , Vacunas/uso terapéutico , Angiotensinas/inmunología , Animales , Anticuerpos Bloqueadores/uso terapéutico , Humanos , Receptor de Angiotensina Tipo 1/análisis , Receptor de Angiotensina Tipo 1/inmunología , Renina/inmunología , Vacunas/efectos adversosRESUMEN
BACKGROUND: We recently reported that murine and cavian heart mast cells are a unique extrarenal source of renin. Ischemia/reperfusion releases this renin leading to local angiotensin formation and norepinephrine release. As mast cells are a primary target of hypersensitivity, we assessed whether anaphylactic mast cell degranulation also results in renin and norepinephrine release. METHODS: Hearts isolated from presensitized guinea pigs were challenged with antigen. RESULTS: Cardiac anaphylaxis was characterized by mast cell degranulation, evidenced by beta-hexosaminidase release and associated with renin and norepinephrine release. Mast cell stabilization with cromolyn or lodoxamide markedly attenuated the release of beta-hexosaminidase, renin and norepinephrine. Renin inhibition with BILA2157 did not affect mast cell degranulation, but attenuated norepinephrine release. CONCLUSIONS: Our findings disclose that immediate-type hypersensitivity elicits renin release from mast cells, activating a local renin-angiotensin system, thereby promoting norepinephrine release. As renin is stored in human heart mast cells, allergic reactions could initiate renin release, leading to local angiotensin formation and hyperadrenergic dysfunction.
Asunto(s)
Degranulación de la Célula/inmunología , Hipersensibilidad Inmediata/inmunología , Mastocitos/inmunología , Miocardio/inmunología , Renina/inmunología , Animales , Antialérgicos/farmacología , Antiasmáticos/farmacología , Degranulación de la Célula/efectos de los fármacos , Cromolin Sódico/farmacología , Cobayas , Hipersensibilidad Inmediata/patología , Técnicas In Vitro , Masculino , Mastocitos/efectos de los fármacos , Mastocitos/enzimología , Mastocitos/fisiología , Miocardio/patología , Norepinefrina/inmunología , Ovalbúmina/inmunología , Ovalbúmina/farmacología , Ácido Oxámico/análogos & derivados , Ácido Oxámico/farmacología , Piridinas/farmacología , Renina/antagonistas & inhibidores , Tiazoles/farmacología , beta-N-Acetilhexosaminidasas/metabolismoRESUMEN
As an important cascade involved in the regulation of blood pressure and volume homeostasis, the renin-angiotensin system (RAS) has been targeted for blood pressure control. In the last decades, the most successful strategy to control the RAS has been the inhibition of the angiotensin-converting enzyme (ACE) and the angiotensin type 1 (AT(1)) receptor. Small-molecule inhibitors targeting these steps have been widely used clinically. However, complete inhibition of the RAS is not achievable by blocking the ACE or the AT(1) because of the compensatory rise in plasma renin activity, which limits the efficacy of many RAS drugs. Direct inhibition of renin, the first and rate-limiting step in the RAS cascade, is the preferred strategy for controlling the RAS, and much progress has been made in the research and development of renin inhibitors. This review covers the evolution of renin inhibitors and discusses the advantages of renin inhibition at the enzymatic and biosynthetic levels for blood pressure control.